At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 29 enrolled
Drug / intervention
SAGE-217 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Two-Part Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of SAGE-217 in Subjects With Parkinson's Disease
In Brief
A Phase 2 clinical trial evaluating SAGE-217, Levodopa, and 1 other intervention for Parkinson Disease. Completed, enrolled 29 participants across 11 sites.
Detailed Summary
This study assesses the safety, tolerability, pharmacokinetics and efficacy of SAGE-217 in 29 participants with moderate to severe Parkinson's Disease.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsParkinson Disease
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
Enrollment StartNov 2016
First PostedDec 2016
Primary CompletionSep 2017
TodayJul 2026
First PostedDec 22, 2016
Enrollment StartNov 30, 2016
Primary CompletionSep 11, 2017
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 9.5 years ago
Interventions
SAGE-217drug
Levodopadrug
Levodopa (including carbidopa-levodopa) administered as antiparkinsonian agent(s).
Antiparkinsonian Agent(s)drug
Antiparkinsonian agent(s) were administered as a clinical practice as standard of care, which includes levodopa (i.e. levodopa/carbidopa) or dopamine agonists or catechol-O-methyltransferase (COMT) inhibitors or monoamine oxidase (BMAO-B) inhibitors.